Regulatory Affairs In The Pharmaceutical Industry

Regulatory Affairs in the Pharmaceutical Industry is a comprehensive reference that compiles all the information available pertaining to regulatory procedures currently followed by the pharmaceutical industry. Designed to impart advanced knowledge and skills required to learn the various concepts of regulatory affairs, the content covers new drugs, generic drugs and their development, regulatory filings in different countries, different phases of clinical trials, and the submission of regulatory documents like IND (Investigational New Drug), NDA (New Drug Application) and ANDA (Abbreviated New Drug Application). Chapters cover documentation in the pharmaceutical industry, generic drug development, code of Federal Regulation (CFR), the ANDA regulatory approval process, the process and documentation for US registration of foreign drugs, the regulation of combination products and medical devices, the CTD and ECTD formats, and much more.

Download 

GDUFA IV: What’s Changing for ANDA Stakeholders?

The FDA’s draft GDUFA IV Commitment Letter proposes several important enhancements to the generic drug review program for FY2028–FY2032.

Key changes include shorter priority review goals, stronger pre-submission facility correspondence (PFC), Discipline Review Letters (DRLs), improved DMF–ANDA coordination, standardized data requirements, enhanced inspection pathways, and greater performance & financial transparency.

🎯 The overarching objective: fewer review cycles, faster timelines, greater predictability, and stronger early engagement between FDA and generic drug applicants.

This poster provides a quick comparison of GDUFA III vs. the proposed GDUFA IV commitments for regulatory affairs, generic drug manufacturers, and ANDA stakeholders.

📌 Follow Pharmatext for pharma regulatory updates, FDA developments, and industry insights.

🌐 www.pharmatext.co.in

hashtag#GDUFAIV hashtag#GDUFA hashtag#FDA hashtag#USFDA hashtag#ANDA hashtag#GenericDrugs hashtag#PharmaceuticalIndustry hashtag#PharmaRegulatory hashtag#RegulatoryAffairs hashtag#FDAUpdates hashtag#GenericDrugDevelopment hashtag#DMF hashtag#ANDAReview hashtag#PharmaceuticalRegulations hashtag#DrugRegulatory hashtag#PharmaUpdates hashtag#USFDAUpdates hashtag#PharmaIndustry hashtag#Pharmatext hashtag#PharmaRegulatoryAffairs

FDA Drug Review Timelines — A Practical Regulatory Guide

Understanding FDA review timelines is essential for effective regulatory planning and drug development strategy.

This comprehensive guide covers the major FDA drug application pathways, including IND, NDA, ANDA, BLA, and Biosimilars (351(k)), along with their review timelines, performance goals, submission types, FDA meeting timelines, expedited programs, postmarketing requirements, and key development milestones.

🔹 Based on the PDUFA VII Commitment Letter (FY 2023–2027)

🔹 Includes detailed tables, comparisons and practical examples

🔹 Covers FDA review pathways from IND submission through approval and post-approval requirements

🔹 Useful for professionals working in Regulatory Affairs, R&D, Clinical Development, Quality, and Pharmaceutical Management

📥 Read the complete document and strengthen your understanding of FDA regulatory timelines.

🌐 Download Here Free 

#PharmaText #FDA #FDARegulatory #FDADrugReview #IND #NDA #ANDA #BLA #Biosimilars #PDUFAVII #RegulatoryAffairs #PharmaceuticalIndustry #DrugDevelopment #PharmaRegulatory #ClinicalDevelopment #PharmaProfessionals #DrugApproval #FDAApproval #PharmaGrowth

Handbook of Pharmaceutical Manufacturing Formulations, Second Edition: (Six-Volume Set)

An authoritative and practical guide to the art and science of formulating drugs.

With thoroughly revised and expanded content, this Second Edition six-volume set compiles volumes from FDA New Drug Applications, patent applications, and other sources of generic and proprietary formulations to cover the broad spectrum of issues concerning drug manufacturing.

A must-have collection for pharmaceutical manufacturers, educational institutions, and regulatory authorities, this set is an excellent platform for drug companies to benchmark their products and for generic companies to formulate drugs coming off patent.

As the largest reference on pharmaceutical formulations, this handbook also provides guidelines on how to file aNDAs in the shortest possible time, helping pharmaceutical companies to cut costs in the areas of pharmaceutical research and development.

Divided conveniently into two parts—regulatory and manufacturing guidelines, and formulations—each volume in the set covers:

• cGMP compliance
• pre-approval inspections
• stability and bioequivalence testing
• packaging commodity development
• common difficulties in formulating drugs
• changes to aNDAs

Download